| Project/Area Number |
24592395
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Hyogo Medical University (2013-2014)
Kagawa University (2012) |
|---|
Principal Investigator |
WU XIUXIAN 兵庫医科大学, 医学部, 講師 (10346645)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SUZUKI Toru 兵庫医科大学, 医学部, 講師 (00441296)
KANEMATSU Akihiro 兵庫医科大学, 医学部, 准教授 (90437202)
YAMAMO Shingo 兵庫医科大学, 医学部, 教授 (80322741)
杉元 幹史 香川大学, 医学部附属病院, 准教授 (10243768)
筧 善行 香川大学, 医学部, 教授 (20214273)
加藤 琢磨 香川大学, 医学部附属病院, 助手 (70625673)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Keywords | lexatumumab / TRAIL-R2 / 腎癌細胞 / テムシロリムス / mapatumumab / TRAIL-R1 / apoptosis / Lexatumumab / 抗癌剤 / 腎癌培養細胞 / Mapatumumab / Ｌｅｘａｔｕｍｕｍａｂ / アポトーシス / アニソマイシン |
|---|
| Outline of Final Research Achievements |
Development of anti-TRAIL receptor antibody in combination with temsirolimus against advanced renal cell carcinoma was performed. We found: (1) anti-TRAIL death receptor 2 antibody lexatumumab in combination with a new molecular targeted drug temsirolimus had an additive cytotoxic effect, although there was no a synergistic effect; (2) anti-TRAIL death receptor 1 antibody mapatumumab in combination with clinically achievable concentrations of epirubicin or pirarubicin had a synergistic cytotoxic effect; the synergistic effect was due to apoptosis via activation of the caspase cascades; (3) mapatumumab in combination with a protein inhibitor anisomycin had a synergistic cytotoxic effect.
|
